154 related articles for article (PubMed ID: 2006117)
1. Evaluation of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer.
Juniewicz PE; Fetrow N; Marinelli J; Wolf M; Young E; Lamb J; Isaacs JT
Prostate; 1991; 18(2):105-15. PubMed ID: 2006117
[TBL] [Abstract][Full Text] [Related]
2. Effect of the steroidal androgen receptor antagonist Win 49,596 on steroid-induced benign prostatic hyperplasia in the castrate beagle dog.
Juniewicz PE; Lemp BM; Barbolt TA; LaBrie TK; McCarthy M; Reel JR; Batzold FH
Prostate; 1990; 16(1):1-14. PubMed ID: 1689481
[TBL] [Abstract][Full Text] [Related]
3. The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of beagle dogs.
Juniewicz PE; McCarthy M; Lemp BM; Barbolt TA; Shaw C; Hollenbaugh DM; Winneker RC; Reel JR; Batzold FH
Endocrinology; 1990 May; 126(5):2625-34. PubMed ID: 1691701
[TBL] [Abstract][Full Text] [Related]
4. Effects of androgen and antiandrogen treatment on canine prostatic arginine esterase.
Juniewicz PE; Barbolt TA; Egy MA; Frenette G; Dube JY; Tremblay RR
Prostate; 1990; 17(2):101-11. PubMed ID: 2169047
[TBL] [Abstract][Full Text] [Related]
5. Endocrine profile of Win 49596 in the rat: a novel androgen receptor antagonist.
Snyder BW; Winneker RC; Batzold FH
J Steroid Biochem; 1989 Dec; 33(6):1127-32. PubMed ID: 2615357
[TBL] [Abstract][Full Text] [Related]
6. Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs.
Juniewicz PE; Hoekstra SJ; Lemp BM; Barbolt TA; Devin JA; Gauthier E; Frenette G; Dube JY; Tremblay RR
Endocrinology; 1993 Aug; 133(2):904-13. PubMed ID: 8393778
[TBL] [Abstract][Full Text] [Related]
7. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327.
Brooks JR; Berman C; Nguyen H; Prahalada S; Primka RL; Rasmusson GH; Slater EE
Prostate; 1991; 18(3):215-27. PubMed ID: 1850515
[TBL] [Abstract][Full Text] [Related]
8. Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers.
Letsch M; Schally AV; Stangelberger A; Groot K; Varga JL
Eur J Cancer; 2004 Feb; 40(3):436-44. PubMed ID: 14746863
[TBL] [Abstract][Full Text] [Related]
9. Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity.
Luo S; Martel C; Chen C; Labrie C; Candas B; Singh SM; Labrie F
Urology; 1997 Dec; 50(6):913-9. PubMed ID: 9426723
[TBL] [Abstract][Full Text] [Related]
10. The development of Casodex (bicalutamide): preclinical studies.
Furr BJ
Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
[TBL] [Abstract][Full Text] [Related]
11. Effect of the 5 alpha-reductase inhibitor PNU 156765, alone or in combination with flutamide, in the Dunning R3327 prostatic carcinoma model in rats.
Zaccheo T; Giudici D; Panzeri A; di Salle E
Chemotherapy; 1998; 44(4):284-92. PubMed ID: 9681205
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
Zaccheo T; Giudici D; di Salle E
Endocr Relat Cancer; 1999 Sep; 6(3):429-35. PubMed ID: 10516856
[TBL] [Abstract][Full Text] [Related]
13. Effect of cyproterone acetate in comparison to flutamide on the ventral prostate of adult male castrated Copenhagen-Fisher rats and on Dunning R-3327 H tumors.
Donn F; Becker H; Klosterhalfen H; Klein H
Andrologia; 1989; 21(5):462-7. PubMed ID: 2530921
[TBL] [Abstract][Full Text] [Related]
14. Effect of 5-alpha-reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC-3.
Tuttle RM; Loop S; Jones RE; Meikle AW; Ostenson RC; Plymate SR
Prostate; 1994 May; 24(5):229-36. PubMed ID: 8170835
[TBL] [Abstract][Full Text] [Related]
15. Studies on the mechanism of action of Win 49596: a steroidal androgen receptor antagonist.
Winneker RC; Wagner MM; Batzold FH
J Steroid Biochem; 1989 Dec; 33(6):1133-8. PubMed ID: 2615358
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
[TBL] [Abstract][Full Text] [Related]
17. A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats.
Allan G; Lai MT; Sbriscia T; Linton O; Haynes-Johnson D; Bhattacharjee S; Dodds R; Fiordeliso J; Lanter J; Sui Z; Lundeen S
J Steroid Biochem Mol Biol; 2007 Jan; 103(1):76-83. PubMed ID: 17049844
[TBL] [Abstract][Full Text] [Related]
18. Effects of perinatal exposure to flutamide on sex hormone responsiveness in F1 male rats.
Miyata K; Yabushita S; Sano M; Miyashita K; Okuno Y; Matsuo M
J Toxicol Sci; 2003 Aug; 28(3):149-63. PubMed ID: 12974607
[TBL] [Abstract][Full Text] [Related]
19. Comparison of anti-androgenic activity of flutamide, vinclozolin, procymidone, linuron, and p, p'-DDE in rodent 10-day Hershberger assay.
Kang IH; Kim HS; Shin JH; Kim TS; Moon HJ; Kim IY; Choi KS; Kil KS; Park YI; Dong MS; Han SY
Toxicology; 2004 Jul; 199(2-3):145-59. PubMed ID: 15147789
[TBL] [Abstract][Full Text] [Related]
20. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
